SCHEMBL24818366

SCHEMBL24818366

CC(C)CCCCCCNC(=O)CCCCCC(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.52
CASP2 P42575 1/20 0.52
FAAH O00519 3/20 0.50
LMNA P02545 1/20 0.49
PKM P14618 1/20 0.49
NAAA Q02083 1/20 0.48
ALDH1A1 P00352 1/20 0.48
DNM1 Q05193 1/20 0.47
CNR1 P21554 2/20 0.46
HPGD P15428 1/20 0.46
EPHX2 P34913 2/20 0.46
KDM4C Q9H3R0 2/20 0.46
KDM4A O75164 1/20 0.46
PHF8 Q9UPP1 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
TSHR P16473 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10345059 1.00 NAMPT (0.52) NAMPTCASP2FAAHLMNAPKM
SCHEMBL10660707 1.00 NAMPT (0.52) NAMPTCASP2FAAHLMNAPKM
SCHEMBL10345306 1.00 NAMPT (0.52) NAMPTCASP2FAAHLMNAPKM
SCHEMBL19239788 0.94 ALDH1A1 (0.52) NAMPTCASP2FAAHLMNAPKM
SCHEMBL23471810 0.94 ALDH1A1 (0.50) NAMPTCASP2FAAHLMNAPKM
SCHEMBL425951 0.94 ALDH1A1 (0.55) NAMPTCASP2FAAHLMNAPKM
SCHEMBL24810920 0.93 CASP2 (0.65) CASP2FAAHNAAADNM1CNR1
SCHEMBL24982632 0.93 NAMPT (0.48) NAMPTCASP2FAAHLMNAPKM
SCHEMBL10345080 0.93 CASP2 (0.65) CASP2FAAHNAAADNM1CNR1
SCHEMBL10345070 0.93 CASP2 (0.65) CASP2FAAHNAAADNM1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024138105-A1 NOVEL RNA THERAPEUTICS AND USES THEREOF ELI LILLY AND COMPANY (US) 2024-06-27 WO disclosed
US-20230022590-A1 NOVEL RNA THERAPEUTICS AND USES THEREOF ELI LILLY AND COMPANY 2023-01-26 US disclosed
WO-2022271808-A1 NOVEL RNA THERAPEUTICS AND USES THEREOF ELI LILLY AND COMPANY (US) 2022-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230022590-A1 NOVEL RNA THERAPEUTICS AND USES THEREOF RNASE1, TEK, HDGFL3 NAMPT 1007/4885CASP2 4223/4885FAAH 4037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.